The mechanisms of hEag1 channel blockage differ among astemizole, imipramine, and dofetilide, suggesting structural differences between hEag1 and HERG channels.
Answers are grounded in this paper and cite their sources.
Differential hEag1 blockade should not alter prescribing; extends evidence for channel-specific drug interactions in animal models.
The relevance of a point mutation at the C-terminal end of the S6 helix (F468) and the introduction of C-type inactivation in the blockage of hEag1 channels by astemizole, imipramine and dofetilide was tested. C-type inactivation decreased block by astemizole and dofetilide but not imipramine, suggesting different binding sites in the channel. F468C mutation increased IC(50) for astemizole and imipramine but in contrast to HERG channels, only slightly for dofetilide. Together with measurements on recovery of blocking, our observations indicate that the mechanism of hEag1 blockage by each of these drugs is different, and suggest relevant structural differences between hEag1 and HERG channels.
No takes yet. Share an insight, caveat, or question.
Gómez‐Varela et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: